by Usha Govindarajulu | Jan 7, 2022 | Biostatistics, Blog, COVID-19, Healtcare
January 5, 2022 With the ongoing rise in COVID-19 cases due to the Omicron variant of Sars-Cov-2, we searched for some actual studies on the change in vaccine efficacy due to Omicron exposure. In one pre-print article, Buchan et al studied 3,442...
by Usha Govindarajulu | Nov 26, 2021 | Biostatistics, Blog, COVID-19, Healtcare, Professor, Usha Govindarajulu
At home Antigen tests statistical results November 24, 2021 Antigen tests for SARS-CoV-2 are back and are pending more approvals by the current administration. If so, they may be used more often and more frequently to help people get back to a more normal lifestyle....
by Usha Govindarajulu | Nov 10, 2021 | Biostatistics, Blog, Healtcare, Usha Govindarajulu
Pfizer anti-viral November 10, 2021 Pfizer, similar to Merck, has announced the efficacy of their anti-viral drug called PAXLOVID against SARS-CoV-2. The reported 89% efficacy against serious disease and 100% efficacy against death and they are making headlines....
by Usha Govindarajulu | Oct 14, 2021 | Biostatistics, Blog, Healtcare, Usha Govindarajulu
Antivirals EUA October 13, 2021 In recent news, Merck and Ridgeback has been hailing an oral anti-viral drug against Sars-CoV-2 that can cut the hospitalization and death rates in half according to their news posted on Oct 1, 2021 on their website. Apparently, the...
by Usha Govindarajulu | Sep 30, 2021 | Biostatistics, Blog, Healtcare, New York, Professor, Usha Govindarajulu
Booster shots for all vaccines September 30, 2021 The Centers for Disease Control and Prevention (CDC) has been promoting booster shots most recently for all vaccines for COVID-19: Pfizer, Moderna, and Johnson & Johnson. However, the Food & Druge...
by Usha Govindarajulu | Sep 15, 2021 | Biostatistics, Blog, Healtcare, Usha Govindarajulu
J&J Booster shots A more recent controversy has come up with the Johnson & Johnson (J&J) vaccine perhaps needing a booster shot sooner than the mRNA based vaccines for COVID-19. A current problem is there is no verifiable data or rather limited...
